CEL-SCI Corp
CVM
Market cap $46.6M

0.7299 USD

-0.0352

4.60%

At close Dec 20, 4:00 PM EST

After hours

0.7748

+0.0449

6.15%

1 day

-4.60%

5 days

5.78%

1 month

16.23%

3 months

-32.42%

6 months

-40.66%

Year to date

-72.87%

1 year

-73.17%

5 years

-92.01%

10 years

-95.22%

About: CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company's core capabilities that include are drug discovery, research, development and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.

Employees: 44

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,809 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

36% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 11

8% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 12

1% less funds holding

Funds holding: 67 [Q2] → 66 (-1) [Q3]

1.82% less ownership

Funds ownership: 11.53% [Q2] → 9.72% (-1.82%) [Q3]

13% less capital invested

Capital invested by funds: $7.25M [Q2] → $6.32M (-$923K) [Q3]

82% less call options, than puts

Call options by funds: $29K | Put options by funds: $159K

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for CVM.

See Analyst Rankings

Financial journalist opinion

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI highlights biological rationale for the use of Multikine in the Confirmatory Registration Head and Neck Cancer Study.

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

Stock Picks From Seeking Alpha's October 2024 New Analysts

In October, 42 new analysts joined Seeking Alpha, sharing diverse investment ideas and strategies, from biotech to real estate. Highlighted strong buy recommendations include MicroStrategy, CorMedix, Hewlett Packard Enterprise, Vertex Pharmaceuticals, and several others. Readers are encouraged to engage with the new analysts, share thoughts on their picks, and join the conversation.

Stock Picks From Seeking Alpha's October 2024 New Analysts

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025.

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--FDA's ODAC decision on checkpoint inhibitors substantiates potential of Multikine to address major treatment gap for PD-L1 negative cancer patients.

FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI selects Ergomed as CRO as it gears up for Confirmatory FDA Registration Study of Multikine in Head and Neck Cancer.

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #ESMO2024--CEL-SCI's Multikine Increased 5-Year Survival Rate in Locally Advanced Resectable Head & Neck Cancer Patients Deemed to be in the Treatment Group.

CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

The UK's Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--The UK's Medicines & Healthcare Products Regulatory Agency grants CEL-SCI a pediatric waiver for Multikine.

The UK's Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation reports third quarter fiscal 2024 financial results, as well as key recent clinical and corporate developments.

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

CEL-SCI Announces Closing of $10.8 Million Offering

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces closing of $10.8 million offering.

CEL-SCI Announces Closing of $10.8 Million Offering

CEL-SCI Announces Pricing of $10.8 Million Offering

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces pricing of $10.8 million offering .

CEL-SCI Announces Pricing of $10.8 Million Offering

See News Rankings

Charts implemented using Lightweight Charts™